Merck moves Seattle to Boston

When I heard that pharmaceutical company Merck was linkurl:slashing;http://www.the-scientist.com/blog/display/55103/ more than 7,000 jobs across the company, my thoughts immediately went to Eric Schadt and his colleagues at Rosetta Inpharmatics, a Seattle-based Merck subsidiary. I linkurl:profiled;http://www.the-scientist.com/article/display/54801/ Schadt, who heads the company's research genetics department, in our July issue. Recent linkurl:reports;http://www.genome-technology.com/issues/blog

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
When I heard that pharmaceutical company Merck was linkurl:slashing;http://www.the-scientist.com/blog/display/55103/ more than 7,000 jobs across the company, my thoughts immediately went to Eric Schadt and his colleagues at Rosetta Inpharmatics, a Seattle-based Merck subsidiary. I linkurl:profiled;http://www.the-scientist.com/article/display/54801/ Schadt, who heads the company's research genetics department, in our July issue. Recent linkurl:reports;http://www.genome-technology.com/issues/blog/general/150221-1.html seemed to indicate that Merck was essentially dissolving its Seattle research operations, which include Rosetta and other labs involved in the company's genomics efforts. Apparently, I wasn't the only one with that mistaken impression. "Eric [Schadt] sent me a quick note yesterday saying he had over 100 emails on the Seattle facility closure from friends and associates, many of whom have jumped to the same incorrect conclusion that you did - that Merck is shutting down its integrative genomics and molecular profiling departments," a Merck spokesperson wrote to me in an E-mail. That spokesperson assured me, however, that "a majority of the people and the labs in Seattle will be moved to our state-of-the-art basic research facility in Boston." So Schadt's position at Merck is safe? Apparently, yes. "Current plans for the Seattle facility are to close it by 12/2009, so [Schadt] will be continuing his work there and leading his team," the spokesperson wrote. Rather than lopping off whole therapeutic or research areas, such as genomics or molecular profiling, continued the spokesperson, "Merck is taking a long-term, strategic approach to further integrating these valuable technologies, people and resources into its core basic research operations to improve our pipeline productivity." We'll see in the coming months and years what this means to Merck's other employees in Seattle and elsewhere.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies